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Background: Diabetes promotes maladaptive changes in the endothelium that lead to its dysfunction and
contribute to the vascular pathology of diabetes. We have previously reported the up-regulation of galectin-3,
a β-galactoside-binding lectin, in the endothelium and sera of diabetic mice, implicating this molecule in diabetic
vasculopathy and suggesting its potential as a biomarker of the disease. Therefore, we sought to assess the role of
galectin-3 in the vascular pathology of diabetes.
Methods: Galectin-3 knockout mice (KO) and wild-type mice (WT) were fed either a high-fat diet (HFD) (60 %
fat calories) to produce insulin resistant diabetes, or standard chow (12 % fat calories), and their metabolic and
endothelial responses were measured. After 8 weeks, the aortic and skeletal muscle endothelia were isolated by
fluorescence sorting of CD105+/CD45− cells and comprehensive transcriptional analyses were performed. Transcripts
differentially dysregulated by HFD in KO endothelium compared to WT were confirmed by semi-quantitative
RT-PCR, and protein expression was determined by immunofluorescence of aortic and muscle tissue. Ingenuity®
Pathway Analysis was used to identify pathways up-regulated by HFD in the KO, such as the coagulation cascade,
and measurements of blood clotting activity were performed to confirm these results.
Results: KO mice exhibit greater hyperglycemia and impaired glucose tolerance but lower insulin levels on HFD
compared to WT. KO mice demonstrate a more robust transcriptional response to HFD in the vascular endothelium
compared to WT. Transcripts dysregulated in the KO endothelium after HFD are involved in glucose uptake and insulin
signaling, vasoregulation, coagulation, and atherogenesis. One of the most down-regulated transcripts in the endothelium
of the KO after HFD was the glucose transporter, Glut4/Slc2a4. GLUT4 immunofluorescence confirmed lower protein
abundance in the endothelium and muscle of the HFD-fed KO. Prothrombin time was decreased in the diabetic KO
indicating increased coagulation activity.
Conclusions: Galectin-3 deficiency leads to exacerbated metabolic derangement and endothelial dysfunction.
The impaired tissue uptake of glucose in KO mice can be attributed to the reduced expression of GLUT4. Enhanced
coagulation activity in the diabetic KO suggests a protective role for galectin-3 against thrombosis. These studies
demonstrate that galectin-3 deficiency contributes both to the pathogenesis of diabetes and the associated vasculopathy.
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Diabetes promotes maladaptive vascular responses in
numerous tissues, including changes in the endothelium
that contribute to insulin resistance and ultimately, the
vascular pathology of diabetes. Endothelial damage or
dysfunction is the primary cause of the macrovascular
and microvascular complications associated with dia-
betes. Previously, we have developed methods for the
rapid isolation of highly purified endothelial cells from
mice exposed to models of diabetes [1, 2]. Transcrip-
tional analysis of these diabetic endothelial cells revealed
increased abundance of galectin-3 mRNA and protein in
the aortic and muscle endothelium. We also found a
correlation between serum galectin-3 levels and insulin
resistance, implicating this molecule as a potential bio-
marker of diabetic vasculopathy [1]. Human studies have
confirmed an elevation of systemic galectin-3 in type II
diabetic patients compared to healthy individuals [3]. A
recent clinical study has shown that galectin-3 levels
correlate with plasma glucose, C-reactive protein, and
degree of insulin resistance, suggesting its potential as a
biomarker for predicting diabetes and prediabetes [4].
Higher galectin-3 levels have also been associated with
increased risk of vascular complications [5]. In light of
our preliminary findings, we suspected that galectin-3 is
involved in the endothelial dysfunction that leads to the
vascular complications of type II diabetes. Thus, we
sought to determine the role of galectin-3 in the vascular
pathology and metabolic derangement observed in type
II diabetes.
In recent years, the importance of this molecule in dis-
ease pathology and its potential as a therapeutic target
has become increasingly evident. Galectin-3 has been
studied for putative roles in heart failure, fibrosis, cancer,
angiogenesis, and atherosclerosis. Human studies show
that subjects with elevated galectin-3 levels have in-
creased risk for developing heart failure, and blood test-
ing for galectin-3 is now being used to monitor heart
failure [6–8]. Perhaps similar testing could be used to
predict vascular complications in diabetic patients.
Intracellular LGALS3 is involved in pre-mRNA spli-
cing and has been implicated in the regulation of gene
transcription by stabilizing transcription factor binding
[9, 10]. Extracellular LGALS3 interacts with components
of the extracellular matrix as well as cell-surface carbo-
hydrates to influence cell adhesion and migration.
LGALS3 is up-regulated on the endothelial cell surface
during adherence and migration of polymorphonuclear
leukocytes in vitro [11] and may also be involved in me-
diating NG2 proteoglycan-induced motility leading to
the recruitment of endothelial cells to sites of neovascu-
larization [12]. Galectin-3 is also a component of the ad-
vanced glycation endproduct (AGE)–receptor complex
expressed on the surface of endothelial cells, which islinked to the binding and removal of AGEs from the cir-
culation [13]. CHO cells overexpressing LGALS3 spe-
cifically bind AGE-BSA and modified LDLs, leading to
their endocytosis [14]. Galectin-3 deficient mice have
been shown to display increased glomerular accumula-
tion of AGEs in a model of type I diabetes and increased
ox-LDL and lipoprotein products when fed an athero-
genic diet [15, 16].
The galectin-3 knockout has been used to study the
role of galectin-3 in murine models of type I diabetes in-
duced by streptozotocin, where both pro-diabetogenic
and protective roles have been reported [15, 17]. Galectin-
3 protein expression increases in human atherosclerotic
lesions as well as in the aortae of experimental animal
models of diabetes [18, 19]. Galectin-3 deletion or inhib-
ition on the ApoE (−/−) background has been shown to
reduce atherosclerotic lesions and plaques [18, 20], while
galectin-3 knockout mice fed an atherogenic diet for
8 months showed increased lesion area and length com-
pared to wild-type mice [16]. These studies suggest an
important role for galectin-3 in vascular complications.
However, the conflicting reports regarding its role in
diabetes and its associated vasculopathy emphasize the
need for further evaluation.
The goal of our study was to identify the role of this
multifunctional lectin in the development of endothelial
dysfunction induced by type II diabetes. To do this, we
examine the metabolic changes and the endothelial tran-
scriptional response to a high-fat diet in wild-type and
Lgals3-deficient mice. These studies define the role of
galectin-3 in endothelial dysfunction and insulin resist-




Mice homozygous for a targeted deletion within the
galectin-3 gene (KO) [B6.Cg-Lgals3tm1Poi/J, stock no.
006338 Jackson Laboratories (Bar Harbor, ME)] and wild-
type C57BL/6 J (WT) (stock no. 000664) were bred for
these experiments. The galectin-3 knockout was generated
by a 3.7 kb deletion of exons 2–4, including the initiating
codon in exon 2 as previously described [21]. Genetic de-
letion of galectin-3 was confirmed at the DNA level by gel
electrophoresis and also at the RNA and protein level by
real-time PCR and Western blotting (Additional file 1).
Beginning at 8 weeks of age, male KO and WT mice
were allowed to feed ad libitum on a high-fat diet (HFD)
containing 60 % fat calories (BioServ, Frenchtown, NJ,
cat. no. S3282) or a normal chow diet containing 12 %
fat calories (LabDiet, St. Louis, MO, cat. no. 5001) for a
period of 8 weeks. All procedures were approved by the
Institutional Animal Care and Use Committee of the
University of Hawaii.
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Blood glucose and serum insulin levels were measured
before the start of the diet and after 2, 4, 6, and 8 weeks
on their respective diets. Animals were fasted overnight,
and glucometry of tail blood was performed using an
OneTouch Ultra (Lifescan, Milpitas, CA). Two-hundred
μL of blood was collected from the tail vein, and insulin
levels in the separated serum were determined by ELISA
(Mercodia, Sweden). A glucose tolerance test (GTT) was
performed after 5 weeks on the diet. Glucose (1 mg/g of
body weight) was administered i.p. following an over-
night fast, and glucometry of the tail blood was performed
prior to glucose injection and every 20 minutes afterwards
for 2 hrs. The homeostatic model assessment of insulin re-
sistance (HOMA-IR) was calculated using the following
formula: [fasting blood glucose (mg/dL) × fasting insulin
(μIU/mL)] / 405 [22], where 1 mg insulin = 26 IU [23].
Advanced glycation end products (AGEs) in the serum
were measured after 8 weeks of diet. Blood was collected
by cardiac puncture and serum was separated and di-
luted to obtain a protein concentration of 5 mg/mL.
AGEs were quantified by ELISA (Wuhan EIAAB
Science, China, cat.no.E0263m) and normalized to total
protein.
Measurement of AKT phosphorylation
Following 8 weeks on the diet, chow and high-fat fed
mice of each strain received an i.p. injection of insulin
(0.06 U/g body weight in 300 μL of sterile saline); 1–2
animals of each group received vehicle (normal saline).
Fifteen minutes after insulin challenge, animals were
sacrificed and thoracic aorta and skeletal muscle were
harvested and homogenized as previously described [1].
Abundance of phosphorylated AKT and total AKT were
determined by Western Blotting. Briefly, denatured aorta
or muscle protein was separated on 12 % Bis-Tris poly-
acrylamide gels under reducing conditions. Following
transfer and blocking, membranes were incubated over-
night in rabbit anti-mouse phospho-AKT antibody
(serine 473) (Cell Signaling, Beverly, MA, cat.no.9271) at
4 °C and visualized with an Alexa Fluor®568-conjugated
secondary antibody (Invitrogen, Carlsbad, CA) on a
Typhoon® phosphorimager (Amersham). Blots were then
stripped and reprobed for total AKT (Cell Signaling,
cat.no.9272). Band intensity was quantified by densito-
metry using ImageJ [24], and phosphorylated AKT was
normalized to total AKT levels.
Endothelial cell isolation
Following 8 weeks on the diet regimen, animals were
sacrificed by CO2 asphyxiation. In each experiment, for
each diet, pooled cells from 3 KO and 3 WT mice were
collected for each tissue. Aortae from the aortic root
to the iliac bifurcation were dissected. Leg musclesconsisting of the plantaris, gastrocnemius, and biceps
femoris (which are readily dissected as a single group)
were excised. Tissues were placed into ice cold PBS and
freed of adherent fat. The aortic and skeletal muscle tis-
sues from 3 animals were each pooled, minced into
1 mm fragments, and dispersed as previously described
[25]. Suspensions of collagenolytically separated cells were
incubated with anti-mouse CD16/32 (1:500) for 5 min and
then with phycoerythrin-conjugated anti-mouse CD45
(1:800) and anti-mouse CD105 eFluor®450 (1:20) for 25 mi-
nutes on ice (eBiosciences, cat.nos.14-0161, 17–0451, and
48–1051). Immediately before sorting, 5 μl of Dead Cell
Discriminator (Life Technologies, Carlsbad, CA) was ad-
ded per 100 μl of cell suspension. Roughly 10,000 live endo-
thelial cells positive for CD105 staining and negative for
CD45 were isolated with a FACSAria (Becton Dickinson,
Franklin Lakes, NJ) directly into Trizol (Invitrogen,
Carlsbad, CA). RNA was extracted and purified with
RNeasy columns (Qiagen, Valencia, CA) and then ampli-
fied using an Ambion® Amino Allyl MessageAmp kit (Life
Technologies, Carlsbad, CA) according to the manu-
facturer’s protocol to produce approximately 100 μg of
amino-allyl modified cRNA.
Transcriptional analysis
Microarray analyses were performed to determine the
transcriptional responses in aortic and skeletal muscle
endothelium from KO vs. WT mice exposed to either
high-fat diet or control diet for 8 weeks. Amino-allyl
modified cRNA was labeled with Cy3 CyDye™ Post-
Labeling Reactive Dye Pack (GE Healthcare, Waukesha,
WI) according to the manufacturer’s instructions.
Following purification, 1.6 μg of Cy3 dye-labeled cRNA,
as measured by NanoDrop 2000c spectrophotometer
(Thermo Scientific, Bellerica, MA), were combined and
fragmented. Biological triplicate experiments were per-
formed for both tissues and both diets for each strain.
Samples were hybridized overnight to glass slides
spotted with the Whole Mouse Genome Array Kit from
Agilent (Santa Clara, CA, cat. no. G4122F), which in-
cludes 44,000 murine oligonucleotides representing all
known genes and transcripts of the mouse genome
along with positive controls. The set of 3’ biased,
60-mer oligos are synthesized in situ using Agilent
SurePrint technology. Annealed fluorescent labels were
quantified with Agilent dual channel scanner, and data
analysis subsequently performed with GeneSpring® and
Acuity® software. For both the KO and WT strains, tran-
scripts exhibiting up-regulation (a log2 [fold change] >1)
or down-regulation (log2 [fold change] < −1) by HFD vs.
chow diet that were found consistently dysregulated in
all 3 biologically replicate experiments were tabulated
for each tissue. This comparison represents the endo-
thelial response to diabetes in either strain.
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The gene expression data was further interrogated using
QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN
Redwood City, www.qiagen.com/ingenuity). Datasets con-
sisting of all transcripts differentially expressed >0.75 log2
[fold change] by high-fat feeding in the WT and KO
strains were uploaded into IPA®. Over-represented Bio-
logical Functions in the aortic endothelium of each strain
after HFD were identified based on weighted gene co-
expression. IPA was also performed on differentially
regulated transcripts between KO HFD and WT HFD
animals to identify differential Canonical Pathways due to
galectin-3 ablation in addition to the response to HFD.
Real-time PCR
Microarray results were confirmed by semi-quantitative
real-time PCR (qPCR) performed on 3 biological replicate
experiments. Synthesis of cDNA was obtained by reverse
transcription of 1 μg of amplified RNA from the sor-
ted endothelial cells using qScript (Quanta Biosciences,
Gaithersburg, MD). Oligonucleotide primers were de-
signed to generate amplicons 100–200 nucleotides long
which spanned at least one intron. Primer sequences are
listed in Additional file 2. The cDNA representing 5 ng of
total RNA was amplified by PCR performed using SYBR®
green fluorophore (Roche, Indianapolis, IN) in an Applied
Biosystems® 7900HT fast real-time PCR system. A stan-
dard two-phase reaction (95 °C 15 sec, 60 °C 1 min)
worked for all amplifications. Dissociation curves run for
each reaction verified the presence of a single amplicon
peak. Amplicons were also sequenced by 3730XL DNA
Analyzer (Applied Biosystems), and BLAST was used to
verify the alignment of the amplicon sequence with that of
the target transcript (Additional file 2).
Fold changes represent the ratio of HFD to chow diet
expression values determined from the cycle times where
CT, the threshold intensity, was exceeded. The abundance
of Cyclophilin A was assessed in parallel as a loading con-
trol to which the genes of interest were normalized.
Prothrombin time
After 8 weeks of high-fat diet, blood was collected by
cardiac puncture following CO2 asphyxiation into tubes
containing sodium citrate anticoagulant at a ratio of 9:1.
Plasma was separated by performing two centrifugation
steps at 5000 rpm for ten minutes each. Prothrombin
time was assessed using a Diagnostica Stago STArt 4
Hemostasis Analyzer according to the manufacturer’s
protocol. Immediately before measurement, plasma was
diluted 1/5 with Stago diluent buffer.
GLUT4 immunofluorescence
Animals were sacrificed after 8 weeks on the diet regi-
men and perfused with PBS. Segments of the thoracicaorta and the entire skeletal muscle were immediately
frozen in TissueTek® Optimal Cutting Temperature
Compound on dry ice. Ten micrometer sections were
rehydrated in PBS, permeabilized with 0.3 % Triton-
X-100, and incubated overnight with rabbit anti-glucose
transporter GLUT4 antibody (Abcam, Cambridge, MA,
ab654) at 1:50 followed by Alexa Fluor®568 goat anti-
rabbit IgG (Invitrogen) at 1:800. Stained sections were
mounted in fluorescence mounting medium containing
DAPI. Images were collected under controlled exposure
and gain settings with an Eclipse 80i (Nikon, Tokyo,
Japan) with SPOT™ software (SPOT™ Imaging Solutions,
Sterling Heights, MI). Six aortic and 2 skeletal muscle
sections from each of 3 WT and 4 KO mice per diet
group were stained for GLUT4. The mean fluorescence
intensity of GLUT4 staining in the skeletal muscle was
determined using ImageJ to quantify the fluorescence in-
tensity of 20 myofibers from each mouse.
Statistics
Statistical analyses of the metabolic parameters and
GLUT4 quantification were performed using 2-way
ANOVA followed by Bonferroni post-hoc tests. For re-
petitive measurements made over time (GTT, glucose,
insulin), a 2-way ANOVA followed by Bonferroni post-
hoc tests was performed at each time-point. The area
under the curve (AUC) of the glucose tolerance test was
determined using the statistical software in Graphpad.
P-values for pAKT densitometry and prothrombin time
were calculated using a two-tailed, unpaired t-test. Sta-
tistically significant transcriptional dysregulation after
HFD was determined by applying the one sample t-test
function within Acuity® to the [HFD/chow] fold-change
results to calculate a p-value for each transcript. Tran-
scripts differentially dysregulated by HFD in the WT and
KO strains were determined by performing a two-tailed,
unpaired t-test between the two groups.
Results
Metabolic characterization of the galectin-3 (−/−) type II
diabetic mouse model
As expected, both KO and WT mice on HFD have sig-
nificant weight gain compared to chow-fed controls, and
this weight gain is similar between the strains (Fig. 1a).
Before the onset of the diet regimen, it was evident that
Lgals3 (−/−) mice have higher fasting glucose levels than
WT (153 ± 51 mg/dL vs. 95 ± 15 mg/dL, mean ± SD,
n = 21–32, P < 0.0001). During the first 2 weeks of high-
fat feeding, KO mice displayed a sharp increase in fast-
ing glucose levels, which remained high for the duration
of the study; whereas fasting glucose levels of WT mice
on HFD increased at a steady rate, reaching statistical
significance at 4 weeks, and then leveled off (Fig. 1b). By
the completion of the 8 week diet regimen, fasting
Fig. 1 Endocrine Responses of KO vs. WT mice fed a high-fat diet. (a) Weight after 8 weeks of diet (HFD n = 19-23; Chow n = 16-17). Increase in
fasting glucose (b) and insulin (c) levels over the time course of the diet regimen (HFD n = 7-26; Chow n = 4-22). (d) HOMA-IR calculated from
fasting glucose and insulin levels after 8 weeks of diet (n = 9-10). (e) Glucose tolerance test performed by measuring glucose levels every 20 min
after i.p. injection of glucose (1 mg/kg, n= 8-9) and (f) corresponding area under the glucose tolerance curve. (g) Sensitivity of aortic and skeletal muscle
tissues to insulin challenge (60 U/kg) after 8 weeks of high-fat or chow diet measured by western blotting for phosphorylated AKT. Densitometry was
performed using Image J, and pAKT levels are expressed as a percentage of total AKT levels (n= 3-8). Data is shown as mean ± SEM. *P< 0.05;**P< 0.01;
***P< 0.001; †P< 0.05 for the interaction of diet and genotype determined by 2-way ANOVA
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the WT on HFD (Fig. 1b).
Fasting insulin levels were consistently lower in the
KO over the time course of the study until the 8 week
time-point (Fig. 1c). Due to higher glucose levels and
similar or lower insulin levels, homeostatic model as-
sessment of insulin resistance (HOMA-IR) is higher in
KO vs. WT on chow and HFD, but not significantly
(Fig. 1d). After 5 weeks of HFD, both WT and KO mice
have significantly impaired glucose tolerance compared
to chow-fed controls as shown by the GTT, but this im-
pairment is more severe in the KO (Fig. 1e, f ).
Furthermore, exposure to HFD for 8 weeks does not
result in a reduced response to insulin as reflected by
similar levels of skeletal muscle AKT phosphorylation
following an in vivo insulin challenge in both KO and
WT mice on HFD (Fig. 1g, Additional file 3). However, a
greater reduction in phosphorylated AKT levels was ob-
served in aortic tissue lysates from Lgals3 (−/−) mice
after HFD, indicating the onset of vascular insulin resist-
ance (Fig. 1g). After 8 weeks of high-fat feeding, the level
of circulating AGEs in the blood of HFD mice remain
similar to that of chow-fed controls. Furthermore, there is
no difference in AGE levels between the two strains [KO
HFD: 1.8 ± 0.7 ng/mg protein; KO Chow: 1.7 ± 0.3 ng/mg
protein; WT HFD: 1.7 ± 0.3 ng/mg protein; WT Chow:
1.7 ± 0.3 ng/mg protein (mean ± SD, n = 9 for HFD and
n = 7 for chow)].
Endothelial cell isolation
Endothelial cells were sorted by FACS based on positive
expression of the endothelial cell-surface glycoprotein,
endoglin (CD105). Endoglin is a component of the
TGF-β receptor complex and is important in angioge-
nesis [26]. While predominantly expressed in endothe-
lial cells, endoglin may also be expressed on activated
monocytes and tissue macrophages [27]. Therefore, we
also stained for the common leukocyte antigen, CD45,
and excluded all CD45+ cells from our sorting gate. FACS
sorting yielded approximately 10,000 CD105+/CD45−, live
cells from each pooled sample. Figure 2 shows repre-
sentative FACS profiles of skeletal muscle and aortic
tissue digests, with the sorted endothelial cell popula-
tion representing 5.7 % and 6.6 % of the live, CD45−
cell populations.
Using this same technique and applying the same sort-
ing gate on GFP+ endothelial cells from Tie2-GFP mice
showed that approximately 75 % of GFP+ cells also dis-
play a high signal for CD105. The specificity of the
endoglin antibody was also tested on C2C12 muscle
cells, which showed no endoglin positive cells. This
technique was much more specific than sorting based
on CD31 expression and stained a greater number of
GFP+ endothelial cells than TIE2 or CD146 antibodiestested. Additional files 4 and 5 show FACS profiles of
the sorted endothelial population as well as negative
controls and testing of endoglin specificity.
Transcriptional results and pathway analysis
Tables 1 and 2 display fold-change of selected transcripts
with |log2 fold-change [HFD/chow]| >1 in all 3 distinct
aortic or skeletal muscle endothelial hybridization exper-
iments for both strains. These transcripts were selected
based on level of dysregulation, or for their roles in dia-
betic or cardiovascular pathophysiology, or known con-
nection to galectin-3. Complete microarray data may be
found in the Gene Expression Omnibus under record
number GSE57329.
Data analysis using IPA® revealed “Cardiovascular System
Development and Function” as a top over-represented
biological function with dysregulated transcripts presented
in Additional file 6. Analysis of differentially regulated
aortic endothelial transcripts between KO HFD and WT
HFD mice revealed the “Coagulation Cascade” to be a
highly up-regulated pathway in the KO HFD endothelium.
Log2 fold change [KO HFD/WT HFD] of transcripts be-
longing to this canonical pathway are shown in Additional
file 7.
The expression levels of selected dysregulated tran-
scripts were evaluated by qPCR. These genes include
caveolin-3 (Cav3), insulin receptor substrate-1 (Irs-1),
glucose-6-phosphatase (G6pc), the glucose transporter
Glut4 (Slc2a4), resistin-like alpha (Retnla), prostaglandin
F receptor (Ptgfr), ceruloplasmin (Cp), macrophage re-
ceptor with collagenous structure (Marco), lymphatic
vessel endothelial hyaluronan receptor 1 (Lyve1), and
insulin-like growth factor 1 (Igf1) and its receptor,
Igf1r. The real-time PCR expression levels are presented
in Fig. 3 as log2 fold change [HFD/control] for
KO and WT strains. The corresponding fold-changes
derived from the microarray data are also shown for
comparison.
Physiological assessment of coagulation pathway activity
Due to the up-regulation of transcripts involved in the
coagulation pathway in the aortic endothelium from KO
diabetic mice compared to WT diabetic mice, coagula-
tion activity was assessed in the plasma after 8 weeks of
high-fat or chow diet. While no difference in prothrom-
bin time (PT) was observed between chow-fed KO and
WT animals, high-fat-fed KO animals displayed reduced
PT compared to chow-fed controls and high-fat-fed WT
mice (Fig. 4).
GLUT4 expression in skeletal muscle and aortic
endothelium
Immunofluorescence staining for GLUT4 in skeletal
muscle sections from chow- and HFD-fed WT and
Fig. 2 FACS isolation of Galectin-3 (−/−) endothelium. Collagenolytic digests of aortae (a) and leg muscles (b) of Galectin-3 (−/−) and C57BL/6
mice were labeled with eFluor450-Endoglin, PE-CD45, and live/dead stain. Live, Endoglin+/CD45− cells were sorted directly into TRIzol reagent for
subsequent gene expression analysis
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strains after 8 weeks of high-fat feeding compared to
chow-fed controls (Fig. 5). In chow-fed animals, intense
GLUT4 fluorescence was localized to the plasma mem-
brane with staining in the cytosol as well (Fig. 5). KO
mice on either diet displayed less GLUT4 fluorescence
compared to the WT strain. Diabetic KO mice had
greatly reduced levels of GLUT4, especially at the mem-
brane, compared to all other groups (Fig. 5). In the aor-
tic endothelium, similar levels of GLUT4 were observed
in chow and HFD WT animals (Fig. 6). However, KO
mice fed a high-fat diet had less endothelial GLUT4
compared to chow-fed KO mice and WT mice on either
diet (Fig. 6).
Discussion
Galectin-3 (−/−) mice display greater metabolic derange-
ment in response to HFD compared to WT mice, inclu-
ding both extreme hyperglycemia and impaired response
to glucose challenge (Fig. 1). Our study indicates that the
elevated glucose levels observed in the galectin-3 knock-
out may be explained by impaired glucose utilization due
to reduced levels of GLUT4. Our transcriptional data
revealed exacerbated down-regulation of Glut4 mRNA in
the KO, by more than 2-fold in the aortic endothelium
and 4-fold in the muscle endothelium compared to WT
(Fig. 3). Immunofluorescence confirmed the reducedabundance of GLUT4 protein in both tissues of the KO
after high-fat feeding (Figs. 5, 6).
Interestingly, chow-fed KO mice display isolated hy-
perglycemia, which may be useful to elucidate pathways
specifically related to increased glucose. Chow-fed KO
mice also show reduced abundance of GLUT4 protein
relative to WT chow animals. Since GLUT4 is the pri-
mary transporter responsible for glucose uptake into
insulin-sensitive tissues such as muscle and fat, reduced
levels of GLUT4 likely contributes to the hyperglycemia
and metabolic dysfunction observed in the KO.
The down-regulation of Glut4 expression has been re-
ported in several models of diabetes and cardiovascular
disease. It has long been known that high-fat feeding
reduces GLUT4 expression in insulin-sensitive tissues,
such as skeletal muscle and fat [28]. In a rat model of
type II diabetes induced by high-fat feeding and strepto-
zotocin injection, cardiac GLUT4 protein was reduced,
likely contributing to the decrease in glucose metabolism
in the diabetic heart [29]. Isoproterenol treatment has
also been shown to decrease Glut4 expression, while
treatment with the dipeptidyl peptidase 4 inhibitor, vil-
dagliptin, improved Glut4 mRNA expression [30]. In the
aortae of angiotensin II hypertensive mice, GLUT4 ex-
pression was reduced by 46 % [31]. Gaudreault et al. ob-
served more than 50 % reduction in GLUT4 protein in
en face preparations of coronary artery endothelial cells
from STZ-treated rats exposed to hyperglycemia for
Table 1 Aortic endothelial responses of KO and WT mice after
8 weeks of HFD vs. chow
Genbank accession Gene name WT H/C KO H/C
NM_007606 carbonic anhydrase 3 −3.66 −3.81
NM_007617 caveolin 3 1.49 2.91
NM_007728 coagulation factor C homolog −1.42 −2.07
NM_007736 collagen, type IV, alpha 5 0.68 2.17
NM_007925 Elastin 1.06 1.79
NM_007940 epoxide hydrolase 2, cytoplasmic −0.84 −1.42




NM_008966 prostaglandin F receptor 0.98 2.01
NM_009204 solute carrier 2a4 (Glut4) −1.06 −2.19
NM_009325 thromboxane A2 receptor 1.19 1.43
NM_009605 adiponectin, C1Q and collagen
domain containing
−5.47 −4.11
NM_009928 collagen, type XV, alpha 1 1.95 2.96
NM_010171 coagulation factor III 0.83 1.58
NM_010570 insulin receptor substrate 1 0.51 1.34
NM_010766 macrophage receptor with
collagenous structure
1.07 4.14
NM_011101 protein kinase C, alpha 0.75 2.39
NM_011580 thrombospondin 1 −1.71 −0.20
NM_013459 complement factor D (adipsin) −4.26 −4.02
NM_018762 glycoprotein 9 (platelet) −0.50 −2.77
NM_020509 resistin like alpha −4.44 −2.45
NM_021282 cytochrome P450, family 2,
subfamily e, polypeptide 1
−4.50 −4.79
NM_022984 Resistin −4.27 −4.49
NM_026280 matrix-remodelling associated 7 1.27 1.94
NM_028784 coagulation factor XIII, A1 subunit −2.32 −0.97
NM_053185 collagen, type IV, alpha 6 0.76 1.75
NM_153526 insulin induced gene 1 −0.30 −1.34
NM_178793 collagen and calcium binding
EGF domains 1
0.07 1.48
Transcripts shown are dysregulated > 1log2 [fold change] in either KO or WT
compared to their respective chow-fed controls
Table 2 Skeletal muscle endothelial responses of KO and WT
mice after 8 weeks of HFD vs. chow
Genbank accession Gene name WT H/C KO H/C
NM_008491 lipocalin 2 −1.23 −2.06
NM_011784 apelin receptor 1.56 1.52
NM_009325 thromboxane A2 receptor 1.78 1.74
NM_019985 C-type lectin domain
family 1, member b
0.64 −1.03
BC007177 cyclin L1 −0.06 −1.15
NM_010104 endothelin 1 −0.48 −1.15
AK042211 endothelin receptor type A −0.85 −1.44
NM_009605 adiponectin, C1Q and collagen
domain containing
0.26 −1.16
NM_021896 guanylate cyclase 1,
soluble, alpha 3
−1.31 −1.16






NM_007413 adenosine A2b receptor −0.49 −1.35
NM_177687 cAMP responsive element
binding protein-like 2
−1.23 −1.67
NM_008161 glutathione peroxidase 3 −1.84 −1.68
NM_053247 lymphatic vessel endothelial
hyaluronan receptor 1
0.90 −1.20
NM_009805 CASP8 and FADD-like
apoptosis regulator
0.39 −1.02
NM_013459 complement factor D (adipsin) −1.77 −3.65
NM_009928 collagen, type XV, alpha 1 2.59 2.27
NM_011607 tenascin C 2.00 1.11
NM_021281 cathepsin S 3.30 1.45
X70100 fatty acid binding protein 5,
epidermal
1.47 0.94
L38613 glucagon receptor 1.39 0.17
J05020 Fc receptor, IgE, high affinity I 1.37 1.15
NM_011311 S100 calcium binding
protein A4
1.30 2.01
NM_008332 interferon-induced protein with
tetratricopeptide repeats 2
1.05 0.50
NM_008329 interferon activated gene 204 1.18 0.65
NM_008620 guanylate binding protein 4 1.05 0.52
AK087208 endothelial PAS domain
protein 1
−1.06 −0.78
NM_178020 hyaluronoglucosaminidase 3 −1.11 −0.20
AK032692 immediate early response 2 −1.18 −0.36
AK163452 aldehyde dehydrogenase 2,
mitochondrial
−1.33 −0.55
NM_133808 high density lipoprotein
(HDL) binding protein
−0.57 0.05
NM_027286 Angiotensin I converting
enzyme
−1.36 −0.58
Transcripts shown are dysregulated >1log2 [fold change] in either KO or WT
compared to their respective chow-fed controls
Darrow and Shohet Cardiovascular Diabetology  (2015) 14:73 Page 8 of 138 weeks [32]. They also showed altered localization of
GLUT4 from the abluminal to the luminal side of the
endothelial cell derived from diabetic rats [32].
Studies of the Glut4 promoter have identified “high-fat
responsive elements” and PPARγ regulation of transcrip-
tion in adipocytes [33, 34]. In muscle, Glut4 expression
is regulated by several factors including myocyte en-
hancer factor 2 (MEF2), GLUT4 enhancer factor (GEF),
MyoD myogenic proteins, thyroid hormone receptors,
and Kruppel-like factor 15 (KLF15) [35, 36]. These stu-
dies demonstrate that GLUT4 expression is subject to
metabolic and tissue-specific regulation. To our
Fig. 3 Log2 fold change of endothelial transcripts dysregulated by HFD in KO and WT mice. Log2 fold change of endothelial transcripts dysregulated
by high-fat diet vs. chow diet in the aortic endothelium (a) and skeletal muscle endothelium (b) of Galectin-3 (−/−) and WT mice after 8 weeks of
feeding were determined by qPCR and microarray analyses. Data is presented as mean + SEM. *P≤ 0.1, **P < 0.05, and ***P < 0.01 by one sample
t-test. ‡P≤ 0.1 and †P < 0.05 vs. WT
Darrow and Shohet Cardiovascular Diabetology  (2015) 14:73 Page 9 of 13knowledge, we are the first to report a link between
galectin-3 and the expression of GLUT4. Further studies
are necessary to understand the molecular basis of the
expression of Glut4 in endothelial cells and the role of
galectin-3 in the regulation of Glut4 expression.Fig. 4 Activation of the extrinsic coagulation pathway in diabetic KO
mice. Prothrombin time of citrate-anticoagulated plasma from WT
and KO mice fed a high-fat or chow diet for 8 weeks was assessed
by measuring the time to coagulation following the addition of a
calcium thromboplastin reagent using a Diagnostica Stago Start 4
Hemostasis Analyzer. *P <0.05; **P <0.01. N = 3 WT animals and
n = 4-5 KO animalsOur studies show that galectin-3 ablation results in
the down-regulation of Glut4 transcription as well as
decreased abundance of GLUT4 protein. GLUT4 im-
munofluorescence in skeletal muscle sections appears to
indicate a reduced localization of GLUT4 to the cell mem-
brane in galectin-3 (−/−) mice compared to WT. However,
further studies are necessary to determine if galectin-3
directly regulates the cell surface expression of GLUT4
and thereby affects glucose flux across the cell.
It is possible that the elevated glucose levels in the KO
are due to hepatic insulin resistance, which may lead to
increased gluconeogenesis and glycogenolysis. However,
a recent study did not find any up-regulation of proteins
involved in gluconeogenesis in the liver of the KO vs.
WT mice [37]. It is also possible that the dysregulation
of other glucose transporters contributes to the observed
hyperglycemia. Our transcriptional data also revealed
the down-regulation of the insulin-independent glucose
transporter, GLUT1, in the aortic endothelium of the
KO, but to a lesser degree than GLUT4 and not signifi-
cantly different from its down-regulation in WT animals.
However, it is possible that its expression is reduced in
other tissues, contributing to decreased glucose uptake.
We did not find altered expression of GLUT1 in the
Fig. 5 Immunofluorescence staining for GLUT4 protein in the skeletal muscle of WT and KO mice. Ten micrometer, fresh-frozen sections from KO
and WT mice fed a high-fat or chow diet for 8 weeks were incubated overnight with rabbit anti-mouse GLUT4 antibody followed by incubation
with an Alexa Fluor®568-conjugated goat anti-rabbit IgG secondary antibody followed by mounting in fluorescence mounting medium containing
DAPI. Representative images from 3 WT and 4 KO mice per group are shown at 40X magnification. Primary antibody was omitted from the unstained
control. Mean fluorescence intensity of 20 myofibers from 2 sections per animal was quantified using Image J. **P < 0.01; ***P <0.001 by 2-way ANOVA
followed by Bonferroni post-hoc tests. †P < 0.05 for the interaction of diet and genotype by 2-way ANOVA
Darrow and Shohet Cardiovascular Diabetology  (2015) 14:73 Page 10 of 13muscle endothelium, but its expression in whole muscle
tissue of the KO has not been investigated. Similarly, a
recent study on the visceral adipose tissue of the KO did
not observe differential expression of GLUT1 [37].
While WT mice seem to maintain lower glucose levels
by compensating with increased insulin output, insulin se-
cretion in the KO is not proportionally increased (Fig. 1c).
Interestingly, pancreatic insulitis has been observed in KO
mice on chow and HFD, and galectin-3 over-expression
has been shown to protect B-cells against toxicity [38, 37].
It is possible that beta cell destruction or dysfunction re-
sults in reduced insulin production and/or secretion, which
also affects the ability of the KO to regulate blood glucose.
By 5 weeks of HFD, both WT and KO animals display
impaired glucose tolerance as demonstrated by GTT
(Fig. 1e). While first phase insulin release is delayed in
both strains, there is a prolonged second phase insulin
response in diabetic KO animals vs. WT animals, sug-
gesting that KO mice may be experiencing greater
peripheral insulin resistance. After 8 weeks of HFD,
peripheral insulin resistance in the skeletal muscle is
not seen in either KO or WT mice on HFD, as demon-
strated by similar levels of AKT phosphorylation com-
pared to chow-fed controls (Fig. 1g). However, vascular
insulin resistance is observed in the HFD-fed KO after
this diet duration (Fig. 1g), and it is possible thatmuscle insulin resistance may also have earlier onset
in the KO.
Interestingly, circulating levels of advanced glycation
endproducts (AGEs) are similar between both strains
and are not elevated by 8 weeks of high-fat diet. There-
fore, the differential responses we observe between the
KO and WT are likely to be independent of galectin-3’s
role in the uptake of AGEs. Previous studies have attri-
buted the protective effects of galectin-3 in diabetes and
atherosclerosis to an indirect role in the removal of
AGEs from circulation, thereby preventing subsequent
tissue damage and activation of the pro-inflammatory
RAGE-pathway [14, 39]. Our data suggests a direct in-
volvement of galectin-3 in the regulation of glucose me-
tabolism and vascular pathology.
Our assessment of the endothelial response to diabetes
in KO and WT mice has shown a greater transcriptional
response in the aortic endothelium of KO mice, with
twice as many dysregulated transcripts compared to
WT. Transcripts with recognized roles in metabolic
signaling, ECM synthesis, vasoconstriction, coagulation,
and inflammation are more dysregulated in the aortic
endothelium of the KO compared to WT (Fig. 3, Table 1).
For example, the glucose transporter, Glut4, is down-
regulated by HFD in both strains, but its reduction in the
KO is twice as great as WT (Fig. 3). Similarly, expression
Fig. 6 Immunofluorescence staining for GLUT4 protein in aortic cross-sections from WT and KO mice. Ten micrometer, fresh-frozen sections from
KO and WT mice fed a high-fat or chow diet for 8 weeks were incubated overnight with rabbit anti-mouse GLUT4 antibody followed by incubation
with an Alexa Fluor®568-conjugated goat anti-rabbit IgG. Representative images from 3 WT and 4 KO mice per group are shown at 100X magnification
in grayscale. Arrows indicate areas of GLUT4 staining in the endothelial cell cytoplasm. No staining was observed in unstained controls where primary
antibody was omitted (not shown)
Darrow and Shohet Cardiovascular Diabetology  (2015) 14:73 Page 11 of 13of Irs-1, insulin-induced gene 1, Igf1, and glucose-6 phos-
phatase are dysregulated to a greater degree in the KO vs.
WT on HFD (Fig. 3). The exacerbated response of the KO
aortic endothelium to HFD suggests a greater derange-
ment of metabolic signaling in these cells and implicates
LGALS3 in the preservation of such pathways.
In the capillary endothelium of the skeletal muscle,
there was less dysregulation by HFD in both strains
compared to the aortic transcriptional response, sugges-
ting a greater role for galectin-3 in the macrovascular
complications of diabetes compared to microvascular
disease. However, transcripts with roles in glucose ho-
meostasis, atherosclerosis, and matrix remodeling are
differentially regulated by HFD in the KO microvascula-
ture vs. WT (Table 2). Transcripts which serve a protec-
tive role in glucose homeostasis, such as Glut4 and theadenosine A2 receptor, are preferentially down-regulated.
Adenosine A2 receptor knockout mice exhibit impaired
glucose tolerance and insulin signaling [40].
Several ECM components and matrix remodeling pro-
teins are also dysregulated in the diabetic KO endothelium
(Fig. 3, Tables 1 and 2). In the muscle endothelium, a re-
ceptor for hyaluronic acid (HA), Lyve1, is downregulated
6-log2 fold (Fig. 3). Lyve1 is expressed in lymphatic endo-
thelial cells and is involved in the degradation of HA, a
matrix component that facilitates cell migration during
wound healing and inflammation [41]. The downregula-
tion of Lyve1 suggests decreased HA turnover which
could impair wound healing in the diabetic KO.
Transcripts implicated in atherosclerosis are also dys-
regulated in the KO endothelium. HDL binding protein,
which is normally expressed by endothelial cells, is
Darrow and Shohet Cardiovascular Diabetology  (2015) 14:73 Page 12 of 13down-regulated by HFD in the WT but not the KO. This
protein was up-regulated in atherosclerotic lesions in
human coronary arteries [42]. Similarly, transcriptional
up-regulation of the scavenger receptor, Marco, in the
aortic endothelium of the diabetic KO by more than
4-log2 fold over chow-fed controls was observed by array
and qPCR (Fig. 3). This receptor serves a role in the
binding and uptake of modified LDL and has been
shown to be constitutively expressed in endothelial cells
of the lymph nodes [43].
Pathway analysis of the HFD-fed KO and HFD-fed
WT transcriptional profiles revealed the up-regulation of
transcripts involved in the coagulation cascade in the
KO endothelium (Additional file 7). Our physiological
assessment of coagulation activity confirmed that dia-
betic KO mice exhibit reduced prothrombin time com-
pared to diabetic WT mice and chow-fed controls
(Fig. 4). Prothrombin time specifically measures activation
of the extrinsic coagulation pathway activated by tissue
factor. Therefore, the diabetic KO displays increased
activation of the extrinsic coagulation pathway, which has
important implications for diabetic patients where in-
creased activation of the coagulation cascade could pro-
mote thrombotic complications.
Furthermore, the transcript for von Willebrand factor
(vWF), a protein important in platelet activation and
aggregation, is also up-regulated in the endothelium of
HFD KO mice compared to HFD WT mice (Additional
file 7). Recent studies have shown that LGALS3 and
LGALS1 interact directly with vWF in endothelial cells
and in plasma via the N-linked glycans of vWF [44]. The
inhibition of these galectins was associated with in-
creased vWF-platelet string formation and more rapid
thombus formation after injury [44]. Our data suggests
that LGALS3 may protect against thrombus formation
in diabetes by suppressing vWF expression in the
endothelium.
Conclusions
Our analysis of the transcriptional response of the endo-
thelium to an in vivo model of type II diabetes in
galectin-3 deficient vs. wild-type mice has revealed dif-
ferential responses in both aortic and skeletal muscle tis-
sues. The KO displays altered expression of transcripts
with roles in the glucose-insulin signaling pathway, ECM
composition, vasoregulation, redox homeostasis, inflam-
mation, coagulation, atherosclerosis, and endothelial
dysfunction. Down-regulation of GLUT4 mRNA and pro-
tein in the endothelium and muscle of galectin-3 (−/−)
mice may explain the hyperglycemia experienced by these
mice, and suggests a role for galectin-3 in the regulation
of glucose uptake. Transcriptional up-regulation of coagu-
lation and pro-thrombotic factors and increased blood
clotting activity in the plasma from diabetic KO mice alsosuggests a protective role for galectin-3 in mediating
coagulation and thrombosis. The transcriptional findings,
as well as the altered metabolism demonstrated by KO
mice compared to WT mice, suggest that galectin-3 serves
a protective role against the metabolic and hormonal de-
rangements that impinge upon the diabetic endothelium
and lead to its damage and dysfunction.
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